What's in Bukwang Pharmaceutical's pipeline?

Bukwang Pharmaceutical has 6 drugs in our index: 5 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 1 in Phase 1.

Which companies overlap with Bukwang Pharmaceutical's portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/bukwang-pharmaceutical.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-14 · How we verify

Bukwang Pharmaceutical — Portfolio Competitive Intelligence Brief

Bukwang Pharmaceutical pipeline: 5 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

5 marketed 0 filed 0 Phase 3 0 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Target	Area
Clevudine, Adefovir	Clevudine, Adefovir	marketed
Zytiga	Zytiga	marketed	Cytochrome P450 11B2, mitochondrial, Androgen receptor, Cytochrome P450 11B1, mitochondrial	Oncology
Purified hepatitis B surface antigen	Purified hepatitis B surface antigen	marketed
Clevudine 20mg	Clevudine 20mg	marketed
Timebutine	Timebutine	marketed		Other

Therapeutic area mix

Oncology · 1
Other · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Bukwang Pharmaceutical:

Cite this brief

Drug Landscape (2026). Bukwang Pharmaceutical — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/bukwang-pharmaceutical. Accessed 2026-05-14.